| Literature DB >> 30213000 |
Jing Zhang1, Min He, Zhiyong Liu, Yanlin Song, Yuelong Wang, Ruichao Liang, Hongxu Chen, Jianguo Xu.
Abstract
Neutrophil-lymphocyte ratio (NLR) is a poor prognostic factor in many tumors including glioblastoma multiforme (GBM), colorectal, and prostate cancer. The aim of this study was to investigate the prognostic value of preoperative NLR in patients with craniopharyngioma.Around 149 patients of craniopharyngioma surgically were treated at the Department of Neurosurgery, West China Hospital from January 2008 to December 2010, including 84 males and 65 females aged from 6 to 70 years were retrospectively reviewed, and preoperative NLR was analyzed. Overall survival (OS), progression free survival (PFS), and quality of life (QOL) were evaluated.The 5-year OS and PFS rates were 81.21% and 75.84%. Preoperative NLR was significantly correlated with OS (HR = 1.44, 95% CI 1.16-1.79, P = .001) and PFS (HR = 1.46, 95% CI 1.22-1.74, P < .001). The best cut-off value of NLR was found to be 4 based on the receiver operator characteristics (ROC) curve. Patients with NLR ≥4 had a significantly worse QOL (P = .039), lower OS rate (P = .009), and PFS rate (P < .001).Preoperative NLR may be a simple, readily available, and valid predictor of long-term outcome in craniopharyngioma. We suggest that the NLR can provide effective guidance to neurosurgeons for more information about the tumor and prognostic evaluation.Entities:
Mesh:
Year: 2018 PMID: 30213000 PMCID: PMC6156074 DOI: 10.1097/MD.0000000000012375
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Distribution of clinical and prognostic factors, and univariate and multivariate analysis of their association with 5-year progression free survival and overall survival.
Distribution of clinical factors and long-term outcome stratified by NLR.
Figure 1Receiver operator characteristics curve of neutrophil-lymphocyte ratio to predict mortality.
Figure 2Kaplan–Meier curves showing overall survival, stratified by neutrophil-lymphocyte ratio (NLR). The median OS was 77 versus 80 months in patients with NLR ≥4 versus <4. NLR = neutrophil-lymphocyte ratio.
Figure 3Kaplan–Meier curves showing progression free survival, stratified by neutrophil-lymphocyte ratio (NLR). The median PFS was 73 versus 78 months in patients with NLR ≥4 versus <4. NLR = neutrophil-lymphocyte ratio.